Nykode Therapeutics AS (STU:5VB) Interest Income: €1.98 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:5VB Nykode Therapeutics AS STU:5VB
37 GF Score
Price €0.45
GF Value €0.55
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Nykode Therapeutics AS Interest Income?

Nykode Therapeutics AS STU:5VB +9.47% 37 Interest Income is €1.98 Mil as of Jun. 2026. GuruFocus rates STU:5VB with a GF Score™ of 37/100 and a GF Value™ of €0.55 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Nykode Therapeutics AS's interest income for the three months ended in Jun. 2026 was €0.41 Mil. Its interest income for the trailing twelve months (TTM) ended in Jun. 2026 was €1.98 Mil.

Nykode Therapeutics AS Interest Income Historical Data

* Premium members only.

The historical data trend for Nykode Therapeutics AS's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nykode Therapeutics AS Interest Income Chart

Nykode Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Income
Get a 7-Day Free Trial Premium Member Only 0.24 3.48 8.20 6.69 3.04

Nykode Therapeutics AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.94 0.61 0.52 0.45 0.41
STU:5VB
37GF Score
Nykode Therapeutics AS STU:5VB
Interest Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nykode Therapeutics AS Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Income →
What does a Interest Income of €1.98 Mil mean?
Nykode Therapeutics AS (STU:5VB) has a Interest Income of €1.98 Mil as of Jun. 2026. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on Nykode Therapeutics AS and its competitors.
Is Nykode Therapeutics AS's Interest Income too high?
Nykode Therapeutics AS's current Interest Income is €1.98 Mil. Overall, Nykode Therapeutics AS has a GF Score™ of 37/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Interest Income compare to VRTX and REGN?
Nykode Therapeutics AS's Interest Income of €1.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Income for a Biotechnology company?
A good Interest Income depends on the Biotechnology industry context. However, Interest Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Income mean?
A high Interest Income can signal that a stock is expensive relative to its fundamentals. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on Nykode Therapeutics AS and its competitors. Nykode Therapeutics AS's current Interest Income is €1.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (STU:5VB) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.55, compared to a current price of €0.45 — trading 19.1% below its estimated fair value. The current Interest Income is €1.98 Mil. Nykode Therapeutics AS's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Income calculated?
Interest Income is calculated from a company's financial statements. For Nykode Therapeutics AS (STU:5VB), the current Interest Income is €1.98 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nykode Therapeutics AS (STU:5VB) Overvalued in 2026?

Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued. The current stock price of €0.45 is trading 19.1% below its estimated GF Value™ of €0.55. GuruFocus considers Nykode Therapeutics AS to be Modestly Undervalued.

Key valuation signals for STU:5VB:

  • Interest Income: €1.98 Mil
  • GF Value™: €0.55 vs. price of €0.45 (19.1% below fair value)
  • GF Score™: 37/100 with 3 warning signs

No single metric tells the full story. See the STU:5VB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nykode Therapeutics AS Business Description

Address Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
37GF Score

Get the complete analysis for STU:5VB

Interest Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.45
Price
€0.55
GF Value